Expert Interview
A look at the potential of Vertex Phamaceuticals' “Vanza Triple” (vanzacaftor/tezacaftor/deutivacaftor) in patients with cystic fibrosis
Ticker(s): VRTXInstitution: UNC Chapel Hill School of Medicine
- Professor of Medicine, Division of Pulmonary Diseases and Critical Care Medicine
- Currently manages 50+ patients with PAH and is very famliar with Tyvaso and Tyvaso DPI
- Research interests span the fields of lung transplantation and pulmonary arterial hypertension.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
